![]() |
Name |
(5R*,5aR*,9aR*)-4,5,5a,6,7,8,9,9a-Octahydro-6,6,9a-trimethylnaphtho[1,2-c]furan-5-ol
|
Molecular Formula | C15H22O2 | |
IUPAC Name* |
6,6,9a-trimethyl-4,5,5a,7,8,9-hexahydrobenzo[e][2]benzofuran-5-ol
|
|
SMILES |
CC1(C)CCCC2(C)c3cocc3CC(O)C12
|
|
InChI |
InChI=1S/C15H22O2/c1-14(2)5-4-6-15(3)11-9-17-8-10(11)7-12(16)13(14)15/h8-9,12-13,16H,4-7H2,1-3H3/t12-,13-,15+/m0/s1
|
|
InChIKey |
OYDRPAIFPPLNFN-KCQAQPDRSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 234.34 | ALogp: | 3.3 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 33.4 | Aromatic Rings: | 3 |
Heavy Atoms: | 17 | QED Weighted: | 0.734 |
Caco-2 Permeability: | -4.545 | MDCK Permeability: | 0.00002250 |
Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.007 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.033 |
30% Bioavailability (F30%): | 0.611 |
Blood-Brain-Barrier Penetration (BBB): | 0.683 | Plasma Protein Binding (PPB): | 94.13% |
Volume Distribution (VD): | 2.099 | Fu: | 11.15% |
CYP1A2-inhibitor: | 0.07 | CYP1A2-substrate: | 0.368 |
CYP2C19-inhibitor: | 0.284 | CYP2C19-substrate: | 0.592 |
CYP2C9-inhibitor: | 0.264 | CYP2C9-substrate: | 0.463 |
CYP2D6-inhibitor: | 0.238 | CYP2D6-substrate: | 0.84 |
CYP3A4-inhibitor: | 0.078 | CYP3A4-substrate: | 0.286 |
Clearance (CL): | 14.831 | Half-life (T1/2): | 0.132 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.136 |
Drug-inuced Liver Injury (DILI): | 0.035 | AMES Toxicity: | 0.01 |
Rat Oral Acute Toxicity: | 0.952 | Maximum Recommended Daily Dose: | 0.144 |
Skin Sensitization: | 0.143 | Carcinogencity: | 0.917 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.033 |
Respiratory Toxicity: | 0.969 |